{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:18:16Z","timestamp":1777580296626,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To evaluate whether long-term remission of ocular cicatricial pemphigoid (OCP) after withdrawal of immunomodulatory therapy (IMT) is possible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A total of 34 of 464 presenting patients (66 eyes) with biopsy-proven OCP in long-term remission off IMT were identified after finishing a 2-year IMT regimen without active disease (2005-2015). Long-term remission off IMT for OCP was defined as patients withdrawn from IMT \u22651 year lacking clinically detectable progressive scarring according to Foster staging and subjective assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>All 34 patients achieved \u22651 year of clinical remission without IMT following 2 years IMT lacking active disease. Mean onset age of OCP was 67.0 years, and median follow-up time was 63.4 months. Mean duration between OCP onset and IMT initiation was 29.5 months, with a mean sustained remission time of 36.0 months off IMT. The mean duration of IMT prior to remission off IMT was 34.8 months (median 32 months, IQR 27-39.5 months). Commonly, methotrexate was used prior to OCP remission (19 patients; 55.9%). Two patients experienced mild flare-up postremission off IMT at months 25 and 37 and a course of topical steroid appeared to resolve the inflammation. Another patient had active inflammation at last office visit 5 years after discontinuation of IMT and will restart IMT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Long-term remission for OCP off IMT may be achieved after stepladder IMT is implemented and withdrawn. Longer follow-up and more sensitive measures of scarring and inflammation are needed to generate a consensus on the definition of complete remission and on cessation of systemic IMT for OCP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5301\/ejo.5001050","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T10:58:29Z","timestamp":1508410709000},"page":"157-162","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Long-term remission of ocular cicatricial pemphigoid off immunomodulatory therapy"],"prefix":"10.1177","volume":"28","author":[{"given":"Caiyun","family":"You","sequence":"first","affiliation":[{"name":"Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, MA - USA"},{"name":"Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin - China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Ma","sequence":"additional","affiliation":[{"name":"Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, MA - USA"},{"name":"Ocular Immunology and Uveitis Foundation, Weston, MA - USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"Anesi","sequence":"additional","affiliation":[{"name":"Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, MA - USA"},{"name":"Ocular Immunology and Uveitis Foundation, Weston, MA - USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Stephen Foster","sequence":"additional","affiliation":[{"name":"Massachusetts Eye Research and Surgery Institution (MERSI), Waltham, MA - USA"},{"name":"Ocular Immunology and Uveitis Foundation, Weston, MA - USA"},{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA - USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,5,6]]},"reference":[{"key":"bibr1-ejo.5001050","first-page":"527","volume":"84","author":"Foster CS","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"key":"bibr2-ejo.5001050","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.3.370"},{"key":"bibr3-ejo.5001050","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(91)32209-7"},{"key":"bibr4-ejo.5001050","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.09.049"},{"key":"bibr5-ejo.5001050","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.04.027"},{"key":"bibr6-ejo.5001050","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.11.012"},{"key":"bibr7-ejo.5001050","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2003.11.002"},{"key":"bibr8-ejo.5001050","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.79.3.264"},{"key":"bibr9-ejo.5001050","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)77908-5"},{"key":"bibr10-ejo.5001050","doi-asserted-by":"publisher","DOI":"10.1007\/BF00160769"},{"key":"bibr11-ejo.5001050","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.08.002"},{"key":"bibr12-ejo.5001050","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2015.07.001"},{"key":"bibr13-ejo.5001050","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.129510"},{"issue":"7","key":"bibr14-ejo.5001050","first-page":"731","volume":"6","author":"Taverna JA","year":"2007","journal-title":"J Drugs Dermatol"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/ejo.5001050","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.5301\/ejo.5001050","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/ejo.5001050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:41:12Z","timestamp":1777405272000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.5301\/ejo.5001050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.5301\/ejo.5001050"],"URL":"https:\/\/doi.org\/10.5301\/ejo.5001050","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}